Market Access Row over CF drug funding as NHS rejects Vertex offer Vertex 'astonished and dismayed' by NHS rejection
News A NICE yes for latest immunotherapy Bavencio NICE has recommended Merck KGaA and Pfizer’s Bavencio in previously treated metastatic Merkel Cell Carcinoma, a rare and aggressive form of skin cancer.
Views & Analysis 'Free' pricing in the UK: the influence of NICE and NHS Engl... UK drug pricing: just how free is free pricing, these days?
News NHS drug deal could fund vital cystic fibrosis research - Ve... Vertex wants long-term funding for CF research
News EULAR 26 hears of treatment advances in lupus Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
